These should preferably be given ~ 6cm apart in the same limb. Each subsequent vaccination should preferably be administered alternating between limbs (e.g., L arm  R thigh). 3.2.2 M7824 Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a "flat" dose of 1,200 mg independent of body weight. However lower doses may also be used as per S ection 3.4.3. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in- line filter. In order to mitigate potential infusion -related reactions, premedication with an antihistamine and with acetaminophen (for example, 25- 50 mg diphenhydramine and 500- 650 mg acetaminophen) within approximately 30 to 60 minutes prior to dosing of M7824 is optional and at the discretion of the Investigator. 3.2.3 NHS -IL12 NHS -IL12 will be administered at as dose of 16.8mcg/kg by SC injection every 4 weeks for up to 4 consecutive doses then 8mcg/kg every 4 weeks thereafter . However lower doses may also be used as per S ection 3.4.3 . The dose of NHS -IL12 will be calculated based on the weight of the 40 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 subject determined within 2 weeks prior to the day of drug administration. The dose of NHS -IL12 used for the previous administration can be repeated if the change in the subject’s weight is 10% or less than the weight used for the last dose calculation. 3.3 STUDY INTERVENTION COMPLIANCE All study interventions will be given at NIH and documented in the electronic medical record. 3.4 D OSE MODIFICATIONS 3.4.1 Discontinuation Treatment with individual agents will be discontinued in the case of: • Any Grade 4 or higher adverse drug reactions (ADRs) as defined by CTCAE v5.0 and assessed as possibly related to that agent by the Investigator , except for laboratory values that are asymptomatic or resolve to Grade ≤ 1 or baseline grade within 7 days • Any Grade 3 ADRs possibly attributed to an agent except for any of the following: o Grade 3 flu -like symptoms or fever, as well as associated symptoms of fatigue, headaches, nausea, emesis which can be controlled with conservative medical management. o Tumor flare phenomenon defined as local pain, irritation, or rash localized at sites of known or suspected tumor. o Grade 3 Hgb decrease (< 8.0 g/dL) that is clinically manageable with blood transfusions or erythroid growth factor use does not require treatment discontinuation. o Grade 3 laboratory values that are asymptomatic or resolve to Grade ≤ 1 or baseline grade within 14 days. o Keratoacanthoma and squamous cell carcinoma of the skin. o Any endocrinopathy that can be medically managed with hormone replacement o Any grade 3 adverse drug reaction which can be medically managed with minimal risk to the participant (e.g., placement of a pleural catheter for recurrent inflammatory pleural effusions) and resolves to at least grade one or baseline grade within 14 days. 3.4.2 Dose Delay Individual agents should be withheld for any Grade 2 or 3 ADR possibly attributed to that agent until resolution to Grade ≤ 1 unless the ADR in the opinion of the investigator is not clinically relevant or can be medically managed with minimal risk to the participant. NHS -IL12 may be restarted at any scheduled visit as long as there is at least 1 1 days between doses of this agent . Should a clinically relevant grade 2 or 3 ADR persist for more than 4 weeks, consideration should be given to discontinuing tre atment with that individual agent at the discretion of the investigator. For non- medical logistical reasons, unrelated acute illnesses, or palliative radiation, scheduled assessments and dosing can be delayed up to 2 months. Where at all possible, dosing should be restarted to keep in line with the original treatment schedule. 3.4.3 Dose Modification Participants with dose modifications or skipped doses within DLT period for reasons other than a DLT (e.g., logistical reasons) who do not experience a DLT within the DLT window will not be evaluable for DLTs and will be replaced for the six -participant lead in DLT assessment. 41 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 Participants who have dose modifications or skipped doses within the DLT period for logistical reasons and nevertheless experience a DLT within the DLT period will be considered DLT evaluable. PDS0101 HPV vaccine: Vaccine doses will not be modified but doses may be skipped per investigator discretion . For example, PDS0101 (which targets HPV 16 specifically) may be held for non-HPV 16 tumors per investigator discretion. M7824: Dose s (including starting doses) may be reduced to a 300 or 600 mg flat dose or doses may be skipped. NHS -IL12: All patients , except patients with cervical cancer and prior pelvic radiation and brachytherapy (described in the next paragraph), will receive NHS -IL12 at a starting dose of 16.8 mcg/kg for up to a total of 4 consecutive doses at which time the dose will be reduced to 8 mcg/kg thereafter. Doses may be reduced to 8 mcg/kg at any time after the first dose for grade ≥ 2 flu- like symptoms, fever, or other NHS -IL12 related toxicities . Additionally, doses may be skipped or further dose -reduced to 4 or 6 mcg/kg. For patients who have already received initial starting doses of NHS -IL12 at 8 mcg/kg they may receive NHS -IL12 at 16.8 mcg/kg for up to a total of 4 consecutive doses. In select participants receiving doses of 8 mcg/kg or lower, consideration may be given to every 2 week dosing of this agent. In patients with cervical cancer with prior pelvic radiation and boost brachytherapy where a potenti al higher risk of grade 3 hematuria may exist with the full starting doses of M7824 at 1200 mg and NHS -IL12 at 16.8 mcg/kg, a staring dose of M7824 at 600 mg and NHS -IL12 at 4 mcg/kg will be used instead . If grade 3 or greater hematuria occurs in ≥ 2 out of four of these patients then the starting dose for these patients will be lowered to M7824 at 300 mg and NHS -IL12 at 4 mcg/kg. If grade 3 or greater hematuria occurs in ≥ 2 out of four of these patients when given M7824 at 300 mg and NHS -IL12 at 4 mcg/kg then these patients will no longer to be eligible to enroll on this protocol. On the other hand, if < 2 patients out of four have grade 3 or greater bleeding events when given M7824 at 600 mg and NHS -IL12 at 4 mcg/kg but objective responses are also observed in < 2 out of these four patients then a dose of M7824 at 1200 mg in combination with NHS-IL12 at 4 mcg/kg will be evaluated in these patients. If ≥ 2 patients out of four have grade 3 or greater bleeding events or < 2 out of four patients have objective responses when given M7824 at 1200 mg and NHS -IL12 at 4 mcg/kg then the combination of M7824 at 600 mg and NHS -IL12 at 6 mcg/kg may be evaluated. Stopping Rule: If m ore than one third of enrolled patients have permanently discontinued one or more study agents due to grade 3 or 4 toxicity per guidelines in S ection 3.4.1 or any death has occurred which is at least possibly related to study regimen this will prompt a suspension of accrual and reassessment of available safety information prior to reopening study to accrual. 42 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 3.4.4 Guidelines for Management of Infusion Reactions NCI-CTCAE Grade Treatment Modification for Infused Agent (M7824) Grade 1 – mild Mild transient reaction; infusion interruption not indicated; intervention not indicated. Consider decreasing the infusion rate of the particular agent by 50% and monitoring closely for any worsening.